[Other] Las firmas divergentes del microbioma intestinal asociadas a la edad y al metabolismo modulan el riesgo de enfermedad cardiovascular. |
Reward10points
|
10
THE LANCET - Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel grou...
20
Integrating organoids and organ-on-a-chip devices (nature reviews bioengineering)
10
SpringerLink
10
SpringerLink
30
Anisotropic electronic and plasmonic properties of 2H-TiS2
